Why is enhancing the interferon pathway an attractive approach for treating cancer?What are the novel therapeutic approaches being investigated to harness the innate immune system to enhance the interferon pathway to treat cancer?What are the translational approaches being applied to better study therapeutics that activate the interferon pathway against hematologic and solid tumors and identify the patients who may respond better to these therapeutics? Christine Ward, PhD, Head, oncology Precisi...
Jan 19, 2023•19 min
In this talk, first recorded at the 2022 IO360° Summit, Dr Rachel Haurwitz, CEO, Caribou Biosciences, addresses the big picture view of where the cell therapy field is going and how innovative CRISPR-based editing will help with the treatment of hematologic and solid tumors. Key topics include: Approach that requires highly specific and efficient multiplex genome editingWhat are some of the potential stumbling blocks?What are the tools for solving those challenges?Tackling solid tumors as the ne...
Jan 18, 2023•26 min
Moderated by: Axel Hoos, MD, PhD, CEO, Scorpion Therapeutics Panelists: Jonathan Fassberg, Vice Chairman of Healthcare Investment Banking, OppenheimerIrina Margine, PhD, Principal, Biotech Private Equity, Wellington ManagementAsthika Goonewardene, MBA, Managing Director, Senior Biotech Analyst, Truist SecuritiesGraig Suvannavejh, PhD, Managing Director, Equity Research Biopharmaceuticals & Biotechnology, Mizuho Securities USA Learn more about the IO360° Summit at www.io360summit.com
Jan 17, 2023•45 min
This panel, first recorded at the 2022 IO360° Summit addressed: What are the risks and implications of investing in cell/gene therapy companies who have no clinical data from programs available?Venture company perspectives on what they are investing in and why? • What science needs to be seen in order to invest in either a startup or IPO?What are investors/pharma partners looking for and how does that inform what people should be doing?How do we think about partnerships between organizations? Mo...
Jan 16, 2023•42 min
In this session, first recorded at the 2022 IO360° Summit, Dr Semenza will talk about how his work is impacting cancer immunotherapy. Dr Semenza’s groundbreaking discovery of hypoxia-inducible factors paves the way for the development of drugs that could kill cancer cells by cutting off the oxygen supply tumors need to grow and improve the response to immunotherapies. Key areas addressed include: Regions of intratumoral hypoxia are a common feature of advanced cancersHypoxia-inducible factors in...
Jan 14, 2023•23 min
Neoadjuvant (pre-surgical) immune checkpoint blockade may prevent cancer relapse and progression.This treatment approach is now FDA-approved for resectable triple-negative breast cancer, and hundreds of clinical trials in other cancers are ongoing.Surgical resection specimens collected after several weeks of neoadjuvant ICB offer vast opportunities for predictive biomarker discovery and understanding ICB response/resistance. Suzanne Topalian, MD, Associate Director / Professor of Surgery, Bloomb...
Jan 13, 2023•26 min
Nouhad Husseini, MBA, SVP, Business Development and Corporate Strategy, Regeneron Pharmaceuticals with Allan Shaw, CFO / Founder & Senior Managing Director, Portage Biotech / Shaw Strategic Capital, LLC Learn more about the IO360 Summit at www.io360summit.com
Jan 12, 2023•22 min
What is the impact of targeted radiotherapy on the immune system?What are the implications for combination IO?Current approaches and future direction Moderated by: Michael Groaning, PhD, Global Medical Affairs Lead, Genitourinary, Amgen Panelists: Charles Glaus, PhD, Sr Director, Radiomics & Radiology Biomarkers, Bayer US-PharmaceuticalsJeff Legos, PhD, MBA, EVP, Global Head of Oncology & Hematology Development , NovartisMatthew Silva, PhD, CEO , InvicroOhad Ilovich, PhD, Senior Director...
Jan 11, 2023•30 min
Learn more about the IO360° Summit at www.io360summit.com
Jan 10, 2023•26 min
In this podcast, you will hear a keynote fireside discussion with Dr Robert Langer, MIT, and Dr Ester Caffarel-Salvador, Chiesi USA, from the 2022 PODD Conference regarding current projects in the Langer Lab, how COVID affected the lab’s dynamics and collaborations, challenges in the drug delivery space, and exciting technologies in the pipeline, To learn more about the PODD Conference, please visit PODDConference.com.
Jan 10, 2023•35 min
This panel, first recorded at the 2021 Immuno-Oncology 360° Summit, will bring together chinese biotechs to share how they are partnering with additional IO companies to advance cancer treatments for patients. This will include partnering strategies and decision making. To learn more about the IO360° Summit visit, www.io360summit.com
Jan 09, 2023•30 min
In this session, GSK shares how they delivered on patient and caregiver engagements, especially with communities experiencing the highest COVID burden. They gained insights on study designs, educational pieces and captured patient experiences to enhance HCP/public COVID awareness. GSK will discuss: Value of COVID engagements Novel approaches and mechanisms for finding patients who don’t belong to an organized patient community Overcoming challenges How this initiative could be modeled to help fi...
Jan 06, 2023•19 min
In this session, Janssen shares how they are collaboratively working with patients and sites to advance DCTs and will share engagement methodologies, what they have learned from the perspective of participants and sites, and the direction this has taken them in DCTs. Alyson Gregg, Director Patient Insights, GMA Commercial Operations, Janssen Morgan Wooten, Investigator & Patient Engagement Program Team Leader, Janssen Learn more about the Patients as Partners in Clinical Research conference ...
Jan 05, 2023•18 min
Merck’s iLab53 (a modular 39-foot mobile unit) was used to bring clinical research into community settings as an effort to increase clinical trial awareness and engagement. More specifically: How the iLab53 was created and implemented How Merck is continuing to work to help build trust within communities, and provide increased access to clinical research Challenges, learnings and successes to date How this initiative can be scaled and adapted Susan Manoff, MD, MPH, Executive Director, Office of ...
Jan 04, 2023•20 min
In this session, Sanofi shares how they created and implemented an end-to-end fully integrated patient informed R&D organization that works directly with patients as advisors in 100% of development staged programs from discovery and supporting research pipeline prioritization to registration. Key topics include: Aligning with the patient community’s most pressing needs Gaining insights that established clinical programs and studies and reshaped clinical trial designs and logistics Prioritizi...
Jan 03, 2023•21 min
In this podcast, you will hear a keynote presentation from Dr John Maraganore from the 2022 PODD Conference regarding lessons learned from his 19 years as CEO of Alnylam Pharmaceuticals, leading a team that conquered some very difficult drug delivery challenges. To learn more about the PODD Conference, please visit PODDConference.com.
Jan 03, 2023•31 min
Legal barriers exist for many good reasons, but can block our pathway in making the changes needed to help patients in the current climate. The panel addresses: Protocols that require approval from legal and complianceR&D and compliance, breaking down the silos and working jointly for patient needsHow to bring the patient voice to legal and compliance initiatives that impact patients?What are the next steps? What initiatives could legal/compliance be a part of with patient engagement to gain...
Jan 02, 2023•42 min
Learn more about the IO360° Summit at www.io360summit.com
Jan 02, 2023•14 min
In this session recorded at DPHARM 2021, Merck shares about their proprietary Site Monitoring and Reporting Tool (SMART), an iOS Apple iPad technology that enables “monitoring and deviation management” before, during and after COVID-19. Merck talks about how they got SMART. Merck developed a real-time “scorecard” for sites called Site Health Check, which allows them to see how they are performing in absolute and relative terms compared to other sites. Merck addresses how this really helped in CO...
Dec 31, 2022•46 min
In this session from DPHARM 2021, Gilead shares how they designed, developed and obtained Emergency Use Authorization and Full Approval for Remdesivir for the treatment of COVID-19 in record time. Key topics: How they built new capabilities at an extremely accelerated pace to design and execute the remdesivir trialsThe role of Real World Data (RWD) in remdesivir trials to understand the natural history of the disease, to inform study design and conduct, and support real world effectivenessManagi...
Dec 30, 2022•41 min
In this podcast, you will hear a presentation with Peter Skutnik, BD Medical-Pharmaceutical Systems and Wendy D Woodley, BD Technologies & Innovation, from the 2022 PODD Conference regarding challenges in combination product development, patient-centric device development considerations, as well as case studies in large volume subcutaneous formulations. To learn more about the PODD Conference, please visit PODDConference.com.
Dec 30, 2022•20 min
In this session from DPHARM 2021, Regeneron's Bari Kowal sits down with Craig Lipset to discuss: Driving greater efficiencies in a pandemicA fresh look at solving problemsPrioritizing priorities Speakers: Bari Kowal, Senior Vice President, Head Development Operations & Portfolio Management, RegeneronCraig Lipset, Advisor and Founder, Clinical Innovation Partners
Dec 29, 2022•30 min
In this session recorded at DPHARM 2022, Memorial Sloan Kettering Cancer Center shares about their Connected Care protocol. Digital monitoring of patients has the potential to better the delivery of cancer care through improved patient-provider communication, enhanced symptom and toxicity assessment and management, and optimized engagement across the cancer continuum. Remote monitoring is especially crucial when patients are at high risk for experiencing symptoms or toxicities from treatment. Du...
Dec 28, 2022•19 min
In this session recorded at DPHARM 2022, panelists from Pfizer discuss: Understanding the key steps Pfizer is taking to make remote clinical trials a reality for patientsExploring the cross functional team approach to scaling remote clinical trials across all therapeutic areasExamining the impact of adopting the light speed mindsetReviewing the key learnings and what the voice of the patient data reveals to date Speakers: Tim Joy, Executive Director, Head of Strategic Solutions, PfizerDaniela Gr...
Dec 27, 2022•31 min
This session was recorded at DPHARM 2022. As the life sciences industry’s focus on digital transformation advances at a rapid pace, the opportunity to understand how well your organization stacks up to the rest of the industry around digital maturity in clinical operations can be highly valuable. This session examines a new benchmarking effort to help pharmaceutical companies rank their digital capabilities in clinical operations, codify specific terms that are used readily and leverage insights...
Dec 26, 2022•36 min
This is a session recorded from DPHARM 2022. As the competition to recruit patients for clinical trials increases and sites are burdened by staffing shortages, technology shifts and more, how can innovative trial designs reduce patient, site and investigator burden? Designing for patient centricity – reducing the burden for patients, sites and investigatorsAddressing organizational implementation challengesEngaging in collaborative partnerships and innovation to operationalize and deliver innova...
Dec 23, 2022•32 min
In this session recorded at DPHARM 2022, moderated by Pfizer's Amy Cramer, the panelists discuss patient data. Often the elephant in the room that hinders the advancement of innovation in clinical trials for the benefit of patients in the lack of structured, clean patient data. R&D executives know the ability to garner greater data value from all data sources [clinical trials, EHRs, claims data, etc] is critical to supporting the future of drug development. The continued conundrum is that da...
Dec 22, 2022•24 min
In this session recorded at DPHARM 2022, Pfizer's Judy Sewards is joined by Patient Advocate Barry Nelson. Judy Sewards was one of the top 30 leaders who played a critical role in the success of Pfizer’s Covid-19 vaccine clinical trial program. In her role, she led patient and site communications and engagement. She was responsible for Pfizer’s relationships with the over 150 trial sites who conducted the Covid-19 vaccine clinical trials. She also helped create awareness about the clinical trial...
Dec 21, 2022•31 min
About The Episode When developing and bringing a therapeutic for a rare disease to market, sponsors should think with the end in mind and plan for payer requirements early in protocol design. The economic and clinical value evidence required by payers for market access differs from the clinical efficacy and safety evidence demanded by regulators. Securing approval but lacking market access results in unrealized revenue and, most importantly, patients left untreated. But how do we price and how d...
Dec 21, 2022•30 min
In this podcast, you will hear a presentation from Dr Liping Zhou, AstraZeneca, from the 2022 PODD Conference regarding formulation techniques and developability considerations for LAI peptide delivery, with a case study example. To learn more about the PODD Conference, please visit PODDConference.com.
Dec 20, 2022•22 min
